Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BL-B01D1 |
Synonyms | |
Therapy Description |
BL-B01D1 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and ERBB3 (HER3) linked to a topoisomerase I inhibitor, which potentially decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 2642). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BL-B01D1 | BL B01D1|BLB01D1|BMS986507|BMS 986507|BMS-986507 | EGFR Antibody 60 HER3 (ERBB3) Antibody 23 | BL-B01D1 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and ERBB3 (HER3) linked to a topoisomerase I inhibitor, which potentially decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 2642). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05983432 | Phase I | BL-B01D1 | Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | ESP | 0 |